Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2025-12-26 @ 2:10 AM
NCT ID:
NCT04607005
Pre Assignment Details:
A total of 169 participants were randomized in a ratio of 1:1 to receive a single dose of 100 milligrams per millilitre (mg/mL) mepolizumab or placebo subcutaneously (SC) every 4 weeks during the 52-week of treatment period.
Recruitment Details:
GlaxoSmithKline (GSK) was informed of suspected Good Clinical Practices (GCP) violations in Medipharma, a Japanese site management organization (SMO) which provided site management services to 2 sites for this study, at which 6 participants were enrolled (4 participants in Mepolizumab + Standard of care (SOC) arm and 2 participants in Placebo + SOC arm). Analysis was performed on two sets of population based on GCP non-compliance (Intent to treat (ITT) and ITT excluding Non-GCP Site).
Study:
NCT04607005
Study Brief:
Results Section:
NCT04607005